Novo Nordisk and Septerna announced an exclusive global collaboration
Novo Nordisk and Septerna have announced a global collaboration to develop oral small molecule medicines targeting obesity, type 2 diabetes, and other cardiometabolic diseases. The partnership combines Novo Nordisk’s leadership in metabolic disease with Septerna’s proprietary Native Complex Platform™, which enables drug discovery for G protein-coupled receptors (GPCRs)—a historically challenging but highly promising class of drug targets.
The collaboration reflects a growing industry shift toward scalable, patient-friendly oral therapies and highlights the potential of GPCR-targeted innovation in addressing the global burden of chronic metabolic conditions.
We are proud to have welcomed Novo Nordisk as a Bronze Sponsor for our 2024 Global Conference.
On the plenary stage in Berlin, Nadeem Sarwar, co-founder and Head Transformational Prevention Unit at Novo Nordisk, discussed and debated scientific, business, partnership, and ecosystem solutions needed to shift the paradigm from disease care to health care. [Read more here or watch more ]
Date: May 14th, 2025 | SOURCE: www.novonordisk.com
Join us and our global community of health innovators in Berlin on November 11-12, 2025.